IMNM Q3 2022 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$9M

Net Income

-$9M

EPS (Diluted)

$-0.70

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$31M

Total Liabilities

$7M

Stockholders' Equity

$23M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$9M	-$8M	-10.5%
Net Income	-$9M	-$8M	-10.5%